Radiolabelling study support for the entire development program

Organising a radiolabelled drug development program requires significant forward planning and in-depth scientific expertise in radiosynthetic chemistry, metabolism, and pharmacokinetics (PK).

Choosing a strong and experienced partner is essential to ensure success and seamless progression to regulatory drug approval.

Pharmaron has a strong track record of supporting our clients’ radiolabelled programs from preclinical to clinical development.

Pharmaron’s experienced team of synthetic chemists, analytical chemists, and drug metabolism scientists synthesize and use Carbon-14 and tritium radiolabelled compounds to study the absorption, distribution, metabolism, excretion (ADME), and the fate of a wide variety of compounds in clinical, preclinical, and discovery investigations. We offer unrivaled expertise in conducting metabolism and pharmacokinetic studies using radioisotopes.